AccessMyLibrary provides FREE access to millions of articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
US health authorities receive new drug application for Amarin's Zelapar.(Amarin Corp P.L.C.)(Brief Article)(Company Profile)
M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD
The US Food and Drug Administration (FDA) has accepted for filing and review a new drug application for Amarin Corp Plc's Parkinson's disease treatment Zelapar.
The filing was made by Elan Pharmaceuticals Inc, which holds exclusive licence rights to market and distribute Zelapar in the US. Amarin has an exclusive option to obtain the US rights to Zelapar from Elan. Upon approval of the drug application and exercise of the option, Zelapar will be marketed by Amarin Pharmaceuticals Inc, the pharmaceutical development and marketing subsidiary of Amarin Corp Plc.
Zelapar is based …
-
- Amarin Corp plc announces $26.4 M private placement.
-
News wire article from: Chemical Business Newsbase
December 19, 2005
700+ words
-
- Amarin Corp plc reports 3Q 2010 financial results and positively updates...
-
News wire article from: Chemical Business Newsbase
November 10, 2010
700+ words
-
- Amarin Corp plc announces $17.8 M registered direct offering of American...
-
News wire article from: Asia Africa Intelligence Wire
May 20, 2005
700+ words
-
- Press Release: Amarin Corp plc announces sale of transdermal patch...
-
News wire article from: Chemical Business Newsbase
December 11, 2001
700+ words
-
- NDA Filed for Zelapar.(by Amarin Corp PLC)(Brief Article)
-
Newspaper article from: Drug Discovery & Technology News
June 1, 2002
700+ words
